Results of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice

Aim: to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease.
Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale.
Results. Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period.
Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.

1. Shelygin Yu.A., Ivashkin V.T., Achkasov S.I., Moskalev A.I., Тimerbulatov V.M., Sazhin A.V., et al. Clinical guidelines. Diverticular disease (57.2, 57.3), adults. Koloproktologia. 2024;23(2):10–27. (In Russ.)]. DOI: 10.33878/2073-7556-2024-23-2-10-27

2. Williams S., Bjarnason I., Hayee B., Haji A. Diverticular disease: update on pathophysiology, classification and management. Frontline Gastroenterol. 2023;15(1):50–8. DOI: 10.1136/flgastro-2022-102361

3. Gralnek I.M., Neeman Z., Strate L.L. Acute lower gastrointestinal bleeding. N Engl J Med. 2017;376(11):1054–63. DOI: 10.1056/NEJMcp1603455

4. Carabotti M., Annibale B., Severi C., Lahner E. Role of fiber in symptomatic uncomplicated diverticular disease: A systematic review. Nutrients. 2017;9(2):161. DOI: 10.3390/nu9020161

5. Lahner E., Bellisario C., Hassan C., Zullo A., Esposito G., Annibale B. Probiotics in the treatment of diverticular disease. A systematic review. J Gastrointestin Liver Dis. 2016;25(1):79–86. DOI: 10.15403/jgld.2014.1121.251.srw

6. Boytsov S.A., Lazebnik L.B., Levchenko S.V., Komissarenko I.A. Rational pharmacotherapy of the symptomatic uncomplicated colon diverticular disease. Experimental and Clinical Gastroenterology. 2018;5:86–92. (In Russ.)].

7. Piccin A., Gulotta M., di Bella S., Martingano P., Crocè L.S., Giuffrè M. Diverticular disease and Rifaximin: An evidence-based review. Antibiotics (Basel). 2023;12(3):443. DOI: 10.3390/antibiotics12030443

8. DuPont H.L. Review article: The antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther. 2016;43 Suppl 1:3–10. DOI: 10.1111/apt.13434

9. Chey W.D., Shah E.D., DuPont H.L. Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: A narrative review. Therap Adv Gastroenterol. 2020;13:1756284819897531. DOI: 10.1177/1756284819897531

10. Pietrzak A.M., Dziki A., Banasiewicz T., Reguła J. Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: A retrospective study. Prz Gastroenterol. 2019;14(1):69–78. DOI: 10.5114/pg.2019.83428

11. Bianchi M., Festa V., Moretti A., Ciaco A., Mangone M., Tornatore V., et al. Meta-analysis: Long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011;33(8):902–10. DOI: 10.1111/j.1365-2036.2011.04606.x

12. Ware J. Jr., Kosinski M., Keller S.D. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33. DOI: 10.1097/00005650-199603000-00003

13. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. DOI: 10.1097/00005650-198601000-00007

14. Palsson O.S., Drossman D.A., Jan T., Le Nevé B., Quinquis L., Hassouna R., et al. Gas-related symptoms in the general population: Prevalence, impact and associated factors in a survey of the United States, the United Kingdom, and Mexico. Neurogastroenterol Motil. 2025;20:e70076. DOI: 10.1111/nmo.70076

15. Di Mario F., Miraglia C., Cambiè G., Violi A., Nouvenne A., Franceschi M., et al. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J Investig Med. 2019;67(4):767–70. DOI: 10.1136/jim-2018-000901